Meet us at CPHI Milan 2026
Connecting research, development, manufacturing, and supply to cut through outsourcing complexity and streamline the drug development journey.
Drug development no longer happens in isolated stages
As programs become increasingly interconnected, decisions made in one part of the process often affect outcomes in another.
When biotech and pharma companies work with multiple third-party partners, challenges can arise:
- Repeated handoffs between vendors, increasing complexity as knowledge and processes are transferred
- Limited visibility across the development lifecycle, resulting in disconnected data and decision-making
- Siloed teams and unclear ownership, creating communication gaps and reducing operational efficiency
As a result, critical activities are executed independently, creating a fragmented approach that lacks strategic alignment.
We offer a better way.
Why Thermo Fisher Scientific?
Thermo Fisher Scientific offers a coordinated suite of solutions that integrates CDMO and CRO capabilities across the drug development ecosystem, with services purpose-built to support programs across therapeutic areas and drug modalities.
As your end-to-end partner, we're always looking ahead. During formulation development, we're already considering later-stage manufacturing requirements. As clinical trials progress, we're helping lay the groundwork for global supply chain readiness.
This forward-looking approach helps reduce friction, maintain continuity, and improve decision-making from early development through commercial manufacturing and beyond—ultimately supporting your goal of getting treatments to patients faster.
About CPHI Milan 2026:
As the premier event connecting global industry experts, CPHI unites the world of pharma. From experiences that inspire innovation and drive change to in-person opportunities that foster meaningful relationships year-round, CPHI is your one-stop destination for joining a community dedicated to advancing health.
CPHI Milan 2026 will bring together top suppliers, innovators, and pharmaceutical professionals from across the biotechnology and pharmaceutical supply chain. Many of the industry's leading companies will be in attendance, including Thermo Fisher Scientific. Our team of experts looks forward to seeing you there.
Attend our sessions:
CDMO consolidation: Strategic partnerships or dangerous dependencies
Manufacturing Theater Session, Day 1
October 6, 2026 | 11:35 a.m.–12:20 p.m.
Hannah Spaepen
Senior Director, CMC Portfolio Management EMEA, Pharma Services
Thermo Fisher Scientific
As drug development programs become more complex, decisions about consolidating CDMO partnerships increasingly shape execution, timelines, and program risk. In CMC, where development, manufacturing, quality, and regulatory activities must remain tightly coordinated, those decisions have implications across the entire program, making governance, collaboration, and execution as important as supplier strategy.
Drawing on a CMC portfolio management perspective, Thermo Fisher’s Hannah Spaepen will explore how sponsors evaluate and manage CDMO partnerships to support resilient development programs. The discussion will examine how governance, cross-functional collaboration, and strategic partnership models can help organizations navigate complexity, make informed outsourcing decisions, and execute with greater confidence.
Putting AI to work in drug development: Practical applications that deliver measurable value
Manufacturing Theater Session, Day 2
October 7, 2026 | 1:45–2:10 p.m.
Anil Kane, PhD, MBA
Global Head of Tech & Scientific Affairs, Pharma Services
Thermo Fisher Scientific
Artificial intelligence is generating tremendous interest across pharmaceutical development, but successful implementation depends on more than adopting AI tools. It requires embedding AI into operational workflows that improve quality, accelerate decision-making, and strengthen execution.
This presentation will highlight practical applications of AI across drug development and manufacturing, from technology transfer and predictive formulation modeling to quality operations and manufacturing. Drawing on real-world examples from a global CDMO, attendees will see how AI is being used to accelerate technology transfer, improve early formulation decisions, streamline deviation investigations, enhance manufacturing performance, and strengthen automated visual inspection.
Through these examples, Thermo Fisher’s Anil Kane will demonstrate how targeted AI applications can improve quality, speed, and predictability in drug development programs while complementing scientific expertise and established quality processes in regulated environments.
Schedule a 1:1 at CPHI Milan 2026
Let's begin our journey together by meeting at CPHI Milan 2026 and discussing the specific needs of your drug development program.
Insights and resources
Discover a different kind of CDMO at CPHI
Stay connected to new discoveries, innovations, and expert scientific opinions.
Follow us on social media for the latest up-to-date event happenings.